Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non‐metastatic breast cancer

AIMS: Trastuzumab, an antibody binding to epidermal growth factor receptor‐2 (HER2), has been approved to treat HER2‐positive breast cancer in different settings. This study aimed at evaluating the influence of tumour size on trastuzumab pharmacokinetics (PK) in non‐metastatic breast cancer patients...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Br J Clin Pharmacol
Päätekijät: Bernadou, Guillemette, Campone, Mario, Merlin, Jean‐Louis, Gouilleux‐Gruart, Valérie, Bachelot, Thomas, Lokiec, François, Rezai, Keyvan, Arnedos, Monica, Diéras, Véronique, Jimenez, Marta, Paintaud, Gilles, Ternant, David
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2016
Aiheet:
Pharmacokinetics
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4834606/
https://ncbi.nlm.nih.gov/pubmed/26714164
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12875
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia